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Abstract
Objectives Many radiologists and clinicians still consider
multiple myeloma (MM) and monoclonal gammopathies
(MG) a contraindication for using iodine-based contrast me-
dia. The ESUR Contrast Media Safety Committee performed
a systematic review of the incidence of post-contrast acute
kidney injury (PC-AKI) in these patients.
Methods A systematic search in Medline and Scopus data-
bases was performed for renal function deterioration studies
in patients with MM or MG following administration of
iodine-based contrast media. Data collection and analysis
were performed according to the PRISMA statement 2009.
Eligibility criteria and methods of analysis were specified in
advance. Cohort and case-control studies reporting changes in
renal function were included.
Results Thirteen studies were selected that reported 824
iodine-based contrast medium administrations in 642 patients
withMMorMG, in which 12 unconfounded cases of PC-AKI
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were found (1.6 %). The majority of patients had intravenous
urography with high osmolality ionic contrast media after pre-
paratory dehydration and purgation.
Conclusions MM and MG alone are not risk factors for PC-
AKI. However, the risk of PC-AKI may become significant in
dehydrated patients with impaired renal function.
Hypercalcaemia may increase the risk of kidney damage,
and should be corrected before contrast medium administra-
tion. Assessment for Bence-Jones proteinuria is not necessary.
Key Points
• Monoclonal gammopathies including multiple myeloma are
a large spectrum of disorders.
• In monoclonal gammopathy with normal renal function, PC-
AKI risk is not increased.
• Renal function is often reduced in myeloma, increasing the
risk of PC-AKI.
• Correction of hypercalcaemia is necessary in myeloma be-
fore iodine-based contrast medium administration.
• Bence-Jones proteinuria assessment in myeloma is unneces-
sary before iodine-based contrast medium administration.
Keywords Multiple myeloma .Monoclonal gammopathies .
Contrast media . Acute kidney injury . Renal failure
Abbreviations
ACR American College of Radiology
CI-AKI Contrast-induced acute kidney injury
CIN Contrast-induced nephropathy
CMSC Contrast Media Safety Committee
CRAB Calcium, Renal, Anaemia, Bone
ESUR European Society of Urogenital
Radiology
FLCs Serum free light chains
MeSH Medical Subject Headings
MG Monoclonal gammopathies
MGUS Gammopathies of undetermined
significance
MM Multiple myeloma
PC-AKI Post-contrast acute kidney injury
PRISMA Preferred Reporting Items for
Systematic Reviews and Meta-Analyses
SMM Smouldering myeloma
Introduction
Since 1954, a number of case reports have linked the use of
high osmolality ionic iodine- based contrast media to the de-
velopment of acute renal failure in patients with multiple my-
eloma (MM) and monoclonal gammopathies (MG) who had
undergone excretory urography and/or, less frequently, retro-
grade pyelography, cholecystography or angiography [1, 2].
Concern about the use of iodine-based contrast medium in
myeloma patients has been challenged since the 1980s, when
it was suggested that the deterioration in renal function was
due to dehydration, pre-existing renal failure, diabetes
mellitus, hypercalcaemia and the use of nephrotoxic drugs,
rather than to the iodine-based contrast medium [3].
However, many radiologists and clinicians still consider
MM and MG a contraindication to contrast medium use.
They often require checks for Bence-Jones proteinuria before
contrast-enhanced CT examinations, and deny clinically indi-
cated investigations in myeloma patients. A survey among
2,000 practicing radiologists, members of the American
College of Radiology (ACR), showed that 36% of them never
consider the use of iodine-based contrast media in myeloma
patients [4], and the ACR still considered MM a possible risk
factor for post-contrast acute kidney injury as recently as 2016
[5].
In view of these facts, the ESUR Contrast Media Safety
Committee (CMSC) considered it necessary to undertake a
systematic review of the available literature about the inci-
dence of post-contrast acute kidney injury (PC-AKI) in pa-
tients with MM and MG, in order to produce evidence-based
recommendations for the use of iodine-based contrast media
in these patients. This study and the resulting guidelines were
extensively discussed by the CMSC academic members and
were also reviewed by the representatives of the pharmaceu-
tical companies who are consultants to the Committee. A con-
sensus report was agreed by the CMSC academic members at
their meeting in February 2017.
Clinical features of monoclonal gammopathies
MG include a large spectrum of disorders characterised by
proliferation of neoplastic plasma cells that synthesise an ab-
normal amount of monoclonal immunoglobulins or immuno-
globulin fragments. The clinical manifestations and course of
this group of disorders are heterogeneous ranging from benign
gammopathies of undetermined significance (MGUS), which
are stable for years and do not need any treatment, to
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aggressive myeloma with bone fractures, renal failure and
impaired haemopoiesis at presentation and a poor response
to any treatment.
Until 2014 MG were classified as MGUS, smouldering
myeloma (SMM), symptomatic MM, solitary plasmacytoma
and immunoglobulin light chain amyloidosis [6]. MGUS and
SMM are typically asymptomatic, and were differentiated by
the level of the monoclonal protein and of clonal plasma cells
in the bone marrow. The diagnosis of MM required demon-
strable evidence of damage caused by the neoplastic plasma
cells: hypercalcaemia, renal failure, anaemia and osteolytic
bone lesions, commonly referred to as CRAB features. This
definition ensured that patients with MGUS were not subject-
ed to unnecessary chemotherapy, but in most patients with
SMM, who have true malignancy, it is only a matter of time
before end-organ damage occurs.
In recent years, reliable markers have been identified that
can distinguish patients with SMM who are at imminent risk
of end-organ damage. Also, improvements in myeloma treat-
ment over the last 10 years suggest that therapeutic interven-
tion at the SMM stage in these high-risk patients may improve
quality of the life and overall survival. The main changes in
the new classification [7] include an updated definition ofMM
that includes not only CRAB but also: (1) bone marrow infil-
tration by clonal plasma cells of 60 % or greater; (2) a serum
free-light chains (FLCs) involved/non-involved ratio of 100 or
greater; (3) more than one focal bone or bonemarrow lesion at
least 5 mm in size at MRI. A creatinine clearance less than 40
ml/min is used as the cut off for renal failure. On the basis of
this new classification, patients showing one or more of these
abnormalities should be considered to have MM and should
undergo specific treatment. Although an increased proportion
ofMM patients undergo treatment, there is a larger population
of SMM with high levels of immunoglobulins having haema-
tological follow-up without any treatment. In SMM and MM
patients the high monoclonal FLCs can overwhelm the capac-
ity of the proximal tubule to reabsorb them so that they reach
the distal tubule where they interact with specific proteins
generating myeloma casts. These casts may block glomerular
flow causing tubular atrophy and interstitial fibrosis [8].
Although the risk of renal failure increases with increasing
concentrations of FLCs in the urine, this does not occur in
all patients. In fact, not all monoclonal FLCs are equally neph-
rotoxic: the kidney injury depends partly on the type of FLCs
and partly on environmental factors. At present, it is not pos-
sible to identify the potential nephrotoxicity of particular
FLCs.
As well as the urine concentration of FLCs, there are many
other factors that increase the risk of kidney damage in SMM
and MM. These factors are in part secondary to MM, such as
hypercalcaemia, hyperuricaemia, coexistent amyloidosis, hy-
perviscosity or abuse of non-steroidal anti-inflammatory
drugs, and in part to comorbidity such as pre-existing
nephropathy, diabetesmellitus, hypertension and cardiovascu-
lar disease. In a recent paper [9], the prevalence of renal im-
pairment in a large group of SMM (1,135 cases) was 20 % at
presentation. However, the renal function of a large proportion
of these patients (54 %) improved after anti-myeloma induc-
tion therapy. This indicates that renal damage is reversible
with treatment and that reducing the FLCs is the most impor-
tant factor in protecting renal function. The same study shows
that if patients never recover their renal function, they have a
very short overall survival and early mortality. The goal of
treatment at any stage of the disease is to achieve the maximal
possible response rapidly, with minimal toxicity, and to im-
prove the patient’s performance status.
Methods
For this systematic review, data collection and analysis were
performed according to the guidelines of the PRISMA state-
ment 2009 [10]. Eligibility criteria and methods of analysis
were specified in advance. Cohort studies and case-control
studies reporting changes in renal function in patients with
MM or MG following administration of iodine-based contrast
media were included. Both non-controlled and controlled in-
vestigations, defined as studies in which patients with MM or
MG were directly compared with patients without myeloma
from the same community, were included. Studies in which a
relationship between contrast medium administration and re-
nal function changes could not be confirmed were excluded.
Search strategy
A systematic search in Medline and Scopus databases was
performed for studies of renal function deterioration in pa-
tients with MM or MG after administration of iodine-based
contrast media. The search strategy was peer reviewed by an
information specialist (DU). A combination of (MeSH) terms
such as acute kidney injury, multiple myeloma, monoclonal
gammopathies and synonyms was used. The complete
Medline and Scopus search strategies are shown in Table 1.
The PubMed function ‘Cited references’ and reference lists of
all included articles were screened for additional relevant lit-
erature. A database of retrieved articles was made using end-
note X7.7.1 (Thomson Reuters), and all duplicates were
removed.
Selection of studies
The first selection was made independently by two reviewers
(FS and MB) with 34 and 21 years of experience in diagnostic
imaging, respectively. Selection was based on the title and
abstract without blinding to the authorship or journal. Then,
references in full text that were deemed potentially relevant by
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either or both of the reviewers were retrieved, and evaluated
according to their eligibility criteria. Non-English language
articles were reviewed by native-language speakers to deter-
mine eligibility. No restrictions were imposed in relation to
study design. If eligibility was doubtful, articles were
discussed by the reviewers and were included or excluded
based on consensus.
Data extraction and data analysis
Information from each reference was extracted by two re-
viewers (FS and MB) working independently. The studies
were categorised based on (1) type (systematic review, review
article, case report, cohort or case-control studies); (2) number
of contrast studies and of patients investigated (both myeloma
patients and control patients from the same population, when
present); (3) type of iodine-based contrast medium and route
of administration; (4) possible causes for renal function dete-
rioration other than iodine-based contrast medium administra-
tion; and (5) number of unconfounded associations between
contrast administration and renal function deterioration.
Unconfounded cases of contrast induced acute kidney injury
(CI-AKI) were defined as situations in which post-contrast
acute kidney injury (PC-AKI) could not be explained by co-
morbidity or causes other than contrast medium administra-
tion. The reviewers then graded the methodological quality of
cohort and case-control studies by using the Newcastle-
Ottawa scale for non-randomised studies [11]. Discrepancies
were resolved by consensus.
Finally, based on the literature and the CMSC consensus,
each guideline was graded using the Oxford Centre for
Evidence Based Medicine (OCEBM) 2011 evidence classifi-
cation: Grade A: established scientific evidence, Grade B:
scientific presumption, Grade C: low level of evidence [12].
Recommendations based on CMSC consensus only were giv-
en Grade D because they were based on expert opinion.
Results
The search and selection procedures used are shown in
Fig. 1. Most studies were excluded during title and ab-
stract review because they were not relevant to the clinical
problem being studied. A total of 55 publications were
considered potentially relevant and were retrieved in full
text. Of these, 41 were excluded for a variety of reasons:
14 were case reports, 12 were review articles, two were
in vitro studies in which no patients were investigated and
nine were surveys, letters, consensus documents or edito-
rials. In three studies the number of patients having
iodine-based contrast medium or MM was not reported.
The last paper was not about myeloma.
This left 14 observational studies that met the eligibility
criteria used for this review [2, 13–25] (Table 2); 11 were
retrospective and three were prospective [16, 21, 25].
Thirteen were cohort studies and one was a case-control study
[25]. The Newcastle-Ottawa scores indicated quality levels
ranging between 5 and 9 on a scale of grades 0–9 for cohort
studies and 0–8 for case-control studies, except for one inves-
tigation [17] with a score of 1 (Table 3). This last study report-
ed anecdotally on 18 intravenous urograms in 16 myeloma
patients in whom no complications were observed and it was
excluded from the systematic review. This left 13 studies with
average Newcastle-Ottawa score grade 6.2 for evaluation. Of
these, eight studies in which there was either no control group
or the control group could not be evaluated [18] had lower
scores of 5–6.
The 13 selected studies were markedly heterogeneous
both in relation to type of investigation and contrast medi-
um (Table 2). They report a total of 824 iodine-based con-
trast medium administrations in 642 patients with MM
(639 administrations in 543 patients) or MG (185 admin-
istrations in 99 patients), in which 12 unconfounded cases
of post contrast acute kidney injury were found (1.6 %). In
11 of the studies high osmolality ionic contrast media were
used. Low osmolality non-ionic contrast media were used
in two studies in which contrast-enhanced CT was per-
formed 210 times in 76 patients with myeloma (n=46) or
gammopathies (n=30) [20, 25]. PC-AKI was observed in 4/
210 (1.9 %) cases [20]. These four patients had normal
creatinine levels ranging from 0.9 to 1.3 mg/dl before con-
trast medium administration, and these increased slightly
within 48 h after contrast injection (range: 1.2–1.6 mg/dl).
Table 1 Search strategies
Database: PubMed (http://www.ncbi.nlm.nih.gov/pubmed)
DATE: no limits/last searched November 20 2016
Total: 53
Strategy:
(BAcute kidney injury^[mesh] OR Bkidney diseases^[mesh] OR Bacute
kidney injury^[tiab] OR Brenal function^[tiab] OR
Bnephropathy^[tiab] OR aki[tiab] OR Brenal failure^[tiab] OR
ARF[tiab] ORCIN[tiab]) AND (Bcontrast media^[mesh] OR Bcontrast
media^[tiab] OR Bcontrast medium^[tiab] OR Bcontrast
induced^[tiab]) AND (multiple myeloma[mesh] OR Bmyeloma^[tiab]
OR Bmonoclonal gammopathies^[tiab])
Database: Scopus (http://www.scopus.com)
DATE: no limits/last searched November 20 2016
Total: 116 (26 excluding PubMed duplicates)
Strategy:
TITLE-ABS-KEY (BAcute kidney injury^ OR Bkidney diseases^ OR
Brenal function^ OR Bnephropathy^ OR Baki^ OR Brenal failure^ OR
BARF^ OR BCIN^) AND TITLE-ABS-KEY (Bcontrast media^ OR
Bcontrast medium^ OR Bcontrast induced^) AND TITLE-ABS-KEY
(Bmyeloma^ OR Bmonoclonal gammopathies^)
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Discussion
Contrast-enhanced studies with iodine-based contrast me-
dia are not routinely performed to stage MM or to inves-
tigate MG, but may be required to detect complications of
the disease. However, many radiologists withhold iodine-
based contrast media from all patients with MM or MG
because they are considered at very high risk of acute
kidney injury [4]. Until 2016, the ACR Manual on
C o n t r a s t M e d i a ( v e r s i o n 1 0 . 2 ) s t a t e d t h a t
Bparaproteinaemias, particularly MM, are known to pre-
dispose patients to irreversible renal failure after high os-
molality contrast media administration due to tubular pro-
tein precipitation and aggregation; however, there is no
data predicting risk with the use of low osmolality or
iso-osmolality agents^ [5]. This statement no longer ap-
pears in the 2017 ACR Manual (Version 10.3) [26]. As
early as 1992 McCarthy and Becker [27] reviewed the
literature on renal failure after high osmolality contrast
media, and stated that major risk factors for acute renal
failure in myeloma patients were not intravenous contrast
media as once suspected, but rather hypercalcaemia, de-
hydration, infection and Bence-Jones proteinuria. They
also noted that it was uncertain whether high osmolality
contrast further increases these risks and that some of the
older contrast media precipitate Bence-Jones protein
in vitro.
Our review showed that the literature available is both lim-
ited and heterogeneous. There are a number of case reports.
De Fronzo et al. [2] in 1975 collected 29 published case
Fig. 1 Search and selection
procedures
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reports of acute renal failure in patients with MM who
underwent intravenous urography (16 apparently with base-
line normal renal function and 13 with chronic renal insuffi-
ciency). No randomised and very few controlled trials are
available, and most studies are retrospective. Many studies
were published before 1980. Most of the myeloma patients
had intravenous urography after preparatory dehydration and
purgation and ionic high osmolar contrast media that have
been withdrawn from the market in most countries were used.
Also, a variety of imaging techniques were used and there
were no studies using intra-arterial contrast injection.
Furthermore, different criteria for detecting post-contrast renal
function deterioration were used. Only two studies considered
the use of the non-ionic contrast media that are in wide use
currently in patients with MM and MG. All these features
limit the value of our systematic review.
The recent retrospective study by Pahade et al. [20]
showed that the incidence of AKI following non-ionic
contrast medium administration (ioversol or iodixanol)
in patients with MM with a normal SCr is low and corre-
lates with β2-microglobulin levels (which increase both
with higher tumour burden and diminished renal func-
tion). Additionally, Preda et al. [25] carried out a prospec-
tive study showing that the use of a non-ionic dimer
(iodixanol) is safe in patients with MG and an eGFR
≥60 ml/min/1.73 m2.
Although the evidence provided by the literature is
rather poor, it appears that MM and MG alone cannot be
considered a risk factor for AKI following intravenous
iodine-based contrast medium administration. However,
the risk may become significant when SMM and MM
are associated with impaired renal function [8]. It there-
fore appears that, in cases of SMM or MM with normal
renal function, it is not necessary to measure the urinary
light chains before iodine-based contrast administration.
In fact, if renal function is preserved, urinary light chains
Table 2 Characteristics of included studies
Study, year Study design No. of exams/
patients
Technique Contrast
medium type
Pathology CIN
(unconfounded)
Brown et al. 1964 [15] Retrospective 39/46 U, 43
RP, 3
Iodopyracet,3
Sodium Acetrizoate, 1
Myeloma 4 *
Lasser et al. 1966 [17] Retrospective 18/16 U Unknown Myeloma 0
Morgan et al. 1966 [18] Retrospective
Retrospective
19/18
105/105
U
U
Unknown
Unknown
Myeloma 0 #
0 #
Vix et al. 1966 [22] Retrospective 52/40 U Unknown Myeloma 0
Svoboda et al. 1967 [24] Retrospective 13/13
2/2
U
C
Iodopyracet §
Acetrizoate §
Diatrizoate §
Variety of contrast media §
Myeloma 0
Fateh-Moghadam 1969 [23] Retrospective 55/69 U, 66
RP, 3
Diatrizoate (probably) Monoclonal gammapathies 0¶
Myers et al. 1971 [19] Retrospective 236/201 U, 218
U+RP, 18
Diatrizoate Myeloma 0†
Defronzo et al. 1975 [2] Retrospective 4/4 U Unknown Myeloma 1
Ansari et al. 1976 [13] Retrospective 1** U Diatrizoate Myeloma 0 ß
Baltzer et al. 1978 [14] Retrospective 41/31 U Diatrizoate, 28 ¥
Iothalamate meglumine, 14 ¥
Myeloma 0
Gassmann et al. 1983 [16] Prospective 34/26 U Iothalamate meglumine Myeloma 0
Uchida et al. 1995 [21] Prospective 13/10 U, 5
Unknown 8
Unknown Myeloma 3
Pahade et al. 2011 [20] Retrospective 80/46 CECT Iodixanol, 10
Ioversol, 70
Myeloma 4
Preda et al. 2011 [25] Prospective 130/30 CECT Iodixanol Monoclonal gammapathies 0
*All patients had severe proteinuria. Three, possibly all, had renal failure before urographic examination. Two developed urinary tract infection after
retrograde pyelography
# Two independent patient series from two different hospitals
§ Iodine-based contrast administered to the single patients unknown
¶ Three confounded cases in patients with multiple comorbidities, dehydration and renal failure
† One confounded case in a patient with pre-existing renal failure who developed ARF
ß 25 patients with CIN. One patient with confounded CIN had myeloma. CIN is confounded in this patient because the patient had fluid deprivation the
night before the examination, and septicaemia, and it is not clear whether this was already present at the time of urography
¥ Number of patients extrapolated from reported percentages
CECT contrast-enhanced CT, U urography, RP retrograde pyelography, ARF acute renal failure, C cholangiography
Eur Radiol
are unable to cause renal damage whatever their concen-
tration. Therefore, in patients with normal renal function
there is no need to check for Bence-Jones proteinuria,
since this test cannot be considered as a surrogate bio-
marker of kidney function [8, 20]. When there is renal
impairment, the usual rules for preventing PC-AKI should
be considered, such as the possibility of an alternative
imaging method not using iodine-based contrast media
and volume expansion [28]. If contrast media are required
for clinical reasons in patients with SMM or MM, mea-
suring the serum calcium is much more important than
checking the urinary FLCs. High concentrations of serum
calcium are relatively common in any stage of SMM or
MM, and are an important r isk factor for AKI.
Hypercalcaemia induces vasoconstriction and can inhibit
antidiuretic hormone activity, so causing dehydration,
which further increases the risk of myeloma casts, leading
to worsening of the renal impairment [8]. Haematologists
are fully aware of the risk of hypercalcaemia in SMM and
MM, and serum calcium measurement is now one of the
tests routinely performed in the follow-up of all stages of
the disease. Also, hypercalcaemia is usually symptomatic
causing malaise, constipation, anorexia, nausea, lethargy,
confusion, coma and cardiovascular manifestations such
as shortening of the QT interval and dysrhythmias.
Therefore, it is very unlikely that an imaging method re-
quiring iodine-based contrast medium administration will
be requested without knowledge of the patient’s serum
Table 3 Quality of studies
Study Study design Average Newcastle-Ottawa score
Brown et al. 1964 [15] Retrospective cohort 5
Lasser et al. 1966 [17] Retrospective cohort 1
Morgan et al. 1966 [18] Retrospective cohort 6
Vix et al. 1966 [22] Retrospective cohort 8
Svoboda et al. 1967 [24] Retrospective cohort 5
Fateh-Moghadam 1969 [23] Retrospective cohort 5
Myers et al. 1971 [19] Retrospective cohort 7
Defronzo et al. 1975 [2] Retrospective cohort 5
Ansari et al. 1976 [13] Retrospective cohort 5
Baltzer et al. 1978 [14] Retrospective cohort 9
Gassmann et al. 1983 [16] Prospective cohort 5
Uchida et al. 1995 [21] Prospective cohort 8
Pahade et al. 2011 [20] Retrospective cohort 5
Preda et al. 2011 [25] Prospective case-control 8
Table 4 Multiple myeloma and monoclonal gammopathy patients: ESUR CMSC guidelines
Level of
evidence (*)
• Multiple myeloma and monoclonal gammopathy patients with normal renal function
are not at increased risk of PC-AKI provided that they are well hydrated and that low-
or iso-osmolar iodine-based contrast media are used
B
• Multiple myeloma patients often have reduced renal function, and such patients
are at increased risk of PC-AKI
A
• Multiple myeloma patients often have hypercalcaemia which can increase
the risk of kidney damage.
Correction of hypercalcaemia before contrast medium administration should
be discussed with the haematologist
D
• Assessment for Bence Jones proteinuria before contrast medium administration
is not necessary
A
*Level of Evidence is graded using the Oxford Centre for Evidence Based Medicine (OCEBM) 2011 classification: Grade A: established scientific
evidence, Grade B: scientific presumption, Grade C: low level of evidence. Recommendations based on CMSC consensus only were given Grade D
(expert opinion)
PC-AKI post-contrast acute kidney injury
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calcium. The treatment of hypercalcaemia is usually easy
and includes aggressive re-hydration followed by diuresis
with frusemide, which increases urinary calcium excre-
tion, and intravenous bisphosphonate (pamidronate or zo-
ledronic acid).
Conclusion
Modern non-ionic iodine-based contrast media can safely
be administered to patients with MM or MG who have
normal renal function. However, comorbidity, such as im-
paired renal function and hypercalcaemia, which increases
the risk of AKI, frequently coexists in these patients and
close cooperation between radiologists and referring cli-
nicians is needed for optimal management of these pa-
tients. Simple guidelines are proposed (Table 4).
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